A Quick Test of cognitive speed is sensitive in detecting early treatment response in alzheimer disease

Alzheimer's Research and Therapy

Volumn 2, Issue 5, 2010, Pages

  Palmqvist, Sebastian ^a,b   Minthon, Lennart ^a,b   Wattmo, Carina ^a,b   Londos, Elisabet ^a,b   Hansson, Oskar ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE SPEED QUICK TEST; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MENTAL TEST; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 77957924111     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt53     Document Type: Article

References (41)

1. An estimate of the total worldwide societal costs of dementia in 2005. A Wimo B Winblad L Jonsson, Alzheimer's Dementia 2007 3 81 91 10.1016/j.jalz.2007. 02.001 19595921
2. Alzheimer's disease management. JL Cummings, J Clin Psychiatry 1998 59 Suppl 13 4 5 9771824
3. Epidemiology of dementia and Alzheimer's disease. HC Hendrie, Am J Geriatr Psychiatry 1998 6 3 18 10.1097/00019442-199821001-00002 9581216
4. Cholinesterase inhibitors for Alzheimer's disease. J Birks, Cochrane Database Syst Rev 2006 D005593 16437532
5. Alzheimer's Disease: Donepezil, Galantamine, Rivastigmine (Review) and Memantine: Guidance (amended August 2009). National Institute for Health and Clinical Excellence, TA111. London: National Institute for Health and Clinical Excellence 2007
6. International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia. C Katona G Livingston C Cooper D Ames H Brodaty E Chiu, Int Psychogeriatr 2007 19 345 354 10.1017/ S1041610207005145 17386120 (Pubitemid 46707429)
7. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. A Qaseem V Snow JT Cross Jr MA Forciea R Hopkins Jr P Shekelle A Adelman D Mehr K Schellhase D Campos-Outcalt P Santaguida DK Owens, Ann Intern Med 2008 148 370 378 18316755
8. Multiple rapid automatic naming measures of cognition: normal performance and effects of aging. JM Jacobson NP Nielsen L Minthon S Warkentin EH Wiig, Percept Motor Skills 2004 98 739 753 10.2466/pms.98.3.739-753 15209286
9. Alzheimer's Quick Test cognitive screening criteria for West African speakers of Krio. NP Nielsen EH Wiig, Age Ageing 2006 35 503 507 10.1093/ageing/afl058 16807311
10. EH Wiig NP Nielsen L Minthon S Warkentin, A Quick Test of Cognitive Speed San Antonio, TX: Pearson 2002
11. Parietal lobe activation in rapid, automatized naming by adults. EH Wiig NP Nielsen L Minthon D McPeek K Said S Warkentin, Percept Motor Skills 2002 94 1230 1244 12186245
12. Associations between AQT processing speed and neuropsychological tests in neuropsychiatric patients. NP Nielsen R Ringstrom EH Wiig L Minthon, Am J Alzheimers Dis Other Demen 2007 22 202 210 10.1177/1089253206300417 17606529
13. Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease. NS Foldi RE White LA Schaefer, Int J Geriatr Psychiatry 2005 20 485 488 10.1002/gps.1319 15852461
14. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. B Vellas L Cunha HJ Gertz PP De Deyn K Wesnes G Hammond S Schwalen, Curr Med Res Opin 2005 21 1423 1429 10.1185/030079905X61884 16197661
15. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. MF Folstein SE Folstein PR McHugh, J Psychiatr Res 1975 12 189 198 10.1016/0022-3956(75)90026-6 1202204
16. E Strauss E Sherman O Spreen, A Compendium of Neuropsychological Tests Oxford: Oxford University Press 3 2006
17. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. AK Wallin N Andreasen S Eriksson S Batsman B Nasman A Ekdahl L Kilander M Grut M Ryden A Wallin M Jonsson H Olofsson E Londos C Wattmo M Eriksdotter Jonhagen L Minthon Swedish Alzheimer Treatment Study Group, Dement Geriatr Cogn Disord 2007 23 150 160 10.1159/000098052 17312368
18. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. G McKhann D Drachman M Folstein R Katzman D Price EM Stadlan, Neurology 1984 34 939 944 6610841
19. The mini-mental state examination: a comprehensive review. TN Tombaugh NJ McIntyre, J Am Geriatr Soc 1992 40 922 935 1512391
20. Evaluation of the mini-mental state examination's internal consistency in a community-based sample of Mexican-American and European-American elders: results from the San Antonio Longitudinal Study of Aging. DV Espino MJ Lichtenstein RF Palmer HP Hazuda, J Am Geriatr Soc 2004 52 822 827 10.1111/j.1532-5415.2004.52226.x 15086669
21. Validity of the serial seven procedure. P Karzmark, Int J Geriatr Psychiatry 2000 15 677 679 10.1002/1099-1166(200008)15:8<677::AID-GPS1773.0. CO;2-4 10960879
22. A Quick Test of cognitive speed as a measure of normal aging and aging with dementia. EH Wiig NP Nielsen E Londos L Minthon, Handbook of cognitive aging: causes, processes and effects New York: Nova Science Publishers Inc, Gariépy Q, Ménard R, 2010 chapter 5 151 179
23. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease. EH Wiig P Annas H Basun N Andreasen L Lannfelt H Zetterberg K Blennow L Minthon, Acta Neurol Scand 2010 121 186 193 10.1111/j.1600-0404.2009.01160.x 19785641
24. Individual change after epilepsy surgery: practice effects and base-rate information. GJ Chelune RI Naugle H Lüders J Sedlak IA Awad, Neuropsychology 1993 7 41 52 10.1037/0894-4105.7.1.41
25. Detecting change: a comparison of three neuropsychological methods, using normal and clinical samples. RK Heaton N Temkin S Dikmen N Avitable MJ Taylor TD Marcotte I Grant, Arch Clin Neuropsychol 2001 16 75 91 14590193
26. Detecting significant change in neuropsychological test performance: a comparison of four models. NR Temkin RK Heaton I Grant SS Dikmen, J Int Neuropsychol Soc 1999 5 357 369 10.1017/S1355617799544068 10349298
27. Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS. TN Tombaugh, Arch Clin Neuropsychol 2005 20 485 503 10.1016/j.acn.2004.11.004 15896562
28. Scales as outcome measures for Alzheimer's disease. R Black B Greenberg JM Ryan H Posner J Seeburger J Amatniek M Resnick R Mohs DS Miller D Saumier MC Carrillo Y Stern, Alzheimers Dement 2009 5 324 339 10.1016/j.jalz.2009.05.667 1956010
29. A new rating scale for Alzheimer's disease. WG Rosen RC Mohs KL Davis, Am J Psychiatry 1984 141 1356 1364 6496779
30. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. D Aarsland C Ballard Z Walker F Bostrom G Alves K Kossakowski I Leroi F Pozo-Rodriguez L Minthon E Londos, Lancet Neurol 2009 8 613 618 10.1016/S1474-4422(09)70146-2 19520613
31. Vitamin E and donepezil for the treatment of mild cognitive impairment. RC Petersen RG Thomas M Grundman D Bennett R Doody S Ferris D Galasko S Jin J Kaye A Levey E Pfeiffer M Sano CH van Dyck LJ Thal Alzheimer's Disease Cooperative Study Group, N Engl J Med 2005 352 2379 2388 10.1056/NEJMoa050151 15829527 (Pubitemid 40958434)
32. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. RS Doody SH Ferris S Salloway Y Sun R Goldman WE Watkins Y Xu AK Murthy, Neurology 2009 72 1555 1561 10.1212/01.wnl.0000344650. 95823.03 19176895
33. Effects of a goal-oriented rehabilitation program in mild cognitive impairment: a pilot study. E Londos K Boschian A Linden C Persson L Minthon J Lexell, Am J Alzheimers Dis Other Dementia 2008 23 177 183 10.1177/ 1533317507312622 (Pubitemid 351550910)
34. Global prevalence of dementia: a Delphi consensus study. CP Ferri M Prince C Brayne H Brodaty L Fratiglioni M Ganguli K Hall K Hasegawa H Hendrie Y Huang A Jorm C Mathers PR Menezes E Rimmer M Scazufca Alzheimer's Disease International, Lancet 2005 366 2112 2117 10.1016/S0140-6736(05)67889-0 16360788
35. A descriptive study of Alzheimer's screening results for minority populations. N Radford G McPherson C Cannon, American Speech-Language-Hearing Association Convention, Poster 162 Boston, MA 2007
36. Cognitive functioning and impairment among rural elderly Hispanics and non-Hispanic whites as assessed by the Mini-Mental State Examination. CL Mulgrew N Morgenstern SM Shetterly J Baxter AE Baron RF Hamman, J Gerontol B Psychol Sci Soc Sci 1999 54 223 230 12382591
37. Alzheimer's disease symptom severity in blacks and whites. MF Shadlen EB Larson L Gibbons WC McCormick L Teri, J Am Geriatr Soc 1999 47 482 486 10203126
38. The effects of donepezil in Alzheimer's disease: results from a multinational trial. A Burns M Rossor J Hecker S Gauthier H Petit HJ Moller SL Rogers LT Friedhoff, Dement Geriatr Cogn Disord 1999 10 237 244 10.1159/000017126 10325453
39. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. B Seltzer P Zolnouni M Nunez R Goldman D Kumar J Ieni S Richardson, Arch Neurol 2004 61 1852 1856 10.1001/archneur.61.12.1852 15596605 (Pubitemid 39612945)
40. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. PN Tariot JL Cummings IR Katz J Mintzer CA Perdomo EM Schwam E Whalen, J Am Geriatr Soc 2001 49 1590 1599 10.1111/j.1532-5415.2001.49266.x 11843990
41. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial: Galantamine International-1 Study Group. GK Wilcock S Lilienfeld E Gaens, BMJ 2000 321 1445 1449 10.1136/bmj.321.7274.1445 11110737